LUCD
Lucid Diagnostics Inc.
Set alert
0.40 USD -0.03 -6.36%
0.4032 Day range 0.44
0.328 52-week range 1.47
- YTD
- -62.86%
- 1 year
- -66.27%
- Open
- 0.4145
- Prev close
- 0.4323
- Mkt cap
- 77.30M
- Vol
- 1.71M
- Avg vol
- 4.90M
- EPS
- -0.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.4032
- High
- 0.44
- Forward P/E
- -1.12
- Beta
- 0.00
- Short ratio
- 0.80
- Inst. own
- 4.18%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.90474
- 200-d avg
- 0.87091
- 1y target
- 3.50
Key statistics
- Market cap
- 46.00M
- Enterprise value
- 94.79M
- Trailing P/E
- 0.00
- Forward P/E
- -1.12
- PEG ratio
- 0.00
- Price / sales
- 10.98
- Price / book
- 0.00
- EPS (TTM)
- -1.12
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.19M
- Revenue growth
- 49.70%
- Free cash flow
- -39.47M
- Total cash
- 14.49M
- Total debt
- 13.07M
- Return on equity
- -1007.83%
- Shares outstanding
- 59.34M
- Short % of float
- 1.74%
- 50-day average
- 0.90474
- 200-day average
- 0.87091
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 3.50 +764.6% upside
Now 0.4048
- Target (low)
- 2.00
- Target (mean)
- 3.50
- Target (high)
- 7.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.14667.
Financials — quick view
LUCD Revenue — quarterly 1.47M
LUCD Net income — quarterly -11.69M
LUCD EPS — quarterly -0.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.16 | -0.20 | -0.04 | -25.00% |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -0.20 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.21 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 25, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 15, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
| Nov 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| Nov 14, 2024 | Needham | reit | Buy | Buy |
| Sep 10, 2024 | Ascendiant Capital | main | Buy | Buy |
| Aug 13, 2024 | Canaccord Genuity | main | Buy | Buy |
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- luciddx.com
News
- PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
- Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Lucid Diagnostics Receiving Medicare Payments For Its EsoGuard Esophageal DNA Test; Closed $15M Private Placement Of Its Newly Designated Series C Convertible Prefs To Existing Long-Term Shareholders On October 21
- Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Your note
Sign in to keep a note on LUCD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKLOG LISHAN | Chief Executive Officer | Stock Award(Grant) | May 6, 2024 | 1,166,630 |
| GORDON MICHAEL ADAM | General Counsel | Stock Award(Grant) | May 6, 2024 | 400,000 |
| LAPIDUS STANLEY N | Director | Sale | Sep 25, 2023 | 101,592 |
| MCGRATH DENNIS M | Chief Financial Officer | Stock Award(Grant) | May 6, 2024 | 1,043,570 |
| O'NEIL SHAUN | President | Stock Award(Grant) | May 6, 2024 | 526,763 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Luminus Management, LLC | 1.94% | 1,152,915 | 893.62K | Sep 29, 2024 |
| Vanguard Group Inc | 0.95% | 560,915 | 434.76K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.36% | 213,540 | 165.51K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 0.21% | 126,362 | 97.94K | Sep 29, 2024 |
| Lido Advisors, LLC | 0.17% | 100,016 | 77.52K | Sep 29, 2024 |
| Levin Capital Strategies, LP | 0.11% | 66,528 | 51.56K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.62% | 366,924 | 284.40K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.33% | 193,991 | 150.36K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.17% | 101,556 | 78.72K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 56,571 | 43.85K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 23,997 | 18.60K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 12,873 | 9.98K | Oct 30, 2024 |